Israeli cannabis device maker Syqe Medical, which includes Philip Morris International as a major investor, has signed Teva Pharmaceuticals (NYSE: TEVA) to distribute its inhaler following its approval by the Health Ministry next year. In addition to the distribution agreement, the companies will jointly set up support and training for patients and medical professionals using a dedicated team of nurses.
The pocket-sized Syqe Inhaler uses selective 100 microgram dosing precision that allows patients to control accurately the delivery, attempting to overcome one of the major barriers to adoption of medical cannabis by doctors, the lack of standardization. The company has tested a similar device in hospitals in a clinical trial that demonstrated its dosing precision superiority to other modes of THC administration.
Read Shoshanna Solomon’s “In global first, Teva signs deal to market medical marijuana inhaler”: http://www.timesofisrael.com/in-global-first-teva-signs-deal-to-market-medical-marijuana-inhaler/
